SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 28, 2019 (February 28, 2019)
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
Clonshaugh Business and Technology Park
Coolock, Dublin, D17 E400, Ireland
(Address of Principal Executive Offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☒||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 8.01|| |
On February 28, 2019, Allergan plc made the following statement in response to a release by Appaloosa LP and another shareholder regarding a shareholder proposal that Appaloosa LP has submitted in connection with Allergans Annual General Meeting of Shareholders to be held on May 1, 2019:
Allergans Board of Directors strongly disagrees that an immediate separation of the CEO and Chair positions is warranted. An immediate separation of the role would be highly disruptive to the company and would diminish the companys ability to execute on its strategy to create a world-class global biopharmaceutical business and develop the companys promising product pipeline. It would also do nothing to enhance the Boards effectiveness or the company performance. The Board believes that a separation of the positions with the next leadership change minimizes risk and is in the best interest of shareholders.
Shareholders will be able to obtain free copies of the Proxy Statement and any other documents relating to the Annual General Meeting of Shareholders filed with the SEC by Allergan through the website maintained at the SEC at http://www.sec.gov/ or on Allergans website at http://www.allergan.com. Shareholders are advised to read the Proxy Statement when it is available because it contains important information.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 28, 2019
/s/ A. Robert D. Bailey
A. Robert D. Bailey
EVP & Chief Legal Officer and Corporate Secretary